HMG is a gonadotropin medicine, not a short peptide
Human menopausal gonadotropin (HMG), generically called menotropins, is a biologic gonadotropin preparation with follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. Calling it an "HMG peptide" is chemically misleading: it is not a small synthetic research peptide.
The current U.S. MENOPUR product is purified from the urine of postmenopausal women and is supplied as a specific prescription kit with defined activity, excipients, diluent, and device components.[1] An online vial labeled HMG is not automatically the same finished product.
The approved evidence is narrow
MENOPUR is FDA-approved for development of multiple follicles and pregnancy in ovulatory women as part of an assisted reproductive technology cycle.[1] Its labeling requires evaluation of infertility, exclusion of pregnancy and primary ovarian failure, and treatment by clinicians experienced in infertility care with access to appropriate monitoring.
This grade A evidence does not make "HMG" an approved treatment for every infertility diagnosis, male fertility, testosterone restoration, bodybuilding, weight loss, anti-aging, or general wellness. Other countries and products may have different labels; any statement of approval must name the exact product, jurisdiction, and indication.
Why monitoring is essential
Menotropins can produce abnormal ovarian enlargement and ovarian hyperstimulation syndrome (OHSS). The current label describes potentially rapid fluid accumulation, severe pain, gastrointestinal symptoms, breathing difficulty, reduced urine output, electrolyte disturbances, pulmonary complications, and thromboembolic reactions.[1]
Additional labelled risks include ovarian torsion, multifetal gestation and birth, ectopic pregnancy, spontaneous abortion, and possible ovarian neoplasms after repeated treatment. Ultrasound and/or estradiol monitoring are used to reduce—but cannot eliminate—risk. These are not conditions suitable for a generic self-directed protocol.
Product identity matters
Gonadotropin activity is expressed biologically, and a vial’s label alone cannot demonstrate its actual FSH/LH activity, identity, purity, sterility, or stability. An approved kit’s instructions and diluent apply to that kit; they should not be copied onto a different product.
Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing.[2] Imported, compounded, or research-market HMG must not be represented as an FDA-approved generic of MENOPUR.
What Teloryx does not publish
Because response and risk depend on diagnosis, ovarian reserve, concurrent medicines, serial monitoring, and the exact finished product, Teloryx does not publish a general HMG dose, reconstitution recipe, or cycle schedule. For an approved product, the authoritative sources are its current label, the dispensing pharmacy, and the treating reproductive-medicine team.